You are here

Home » Content

Fibromiyaljili hastalarda serum interlökin-13 (IL-13) düzeyleri

Serum interleukin-13 (IL-13) levels in patients with fibromyalgia

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Fibromyalgia is a disease characterized by widespread chronic pain and specific tender points on clinical examination. The pathogenesis of fibromyalgia is not known, however genetic predisposition, trauma, psychopathologic reasons, viral infections and immunological mechanisms are thought to play a possible role in the pathogenesis. The aim of this study was to determine serum interleukin-13 (IL-13) levels in patients with fibromyalgia. Twenty nine female patients with fibromyalgia and 26 healthy women were enrolled in the study. In order to exclude possible autoimmune and rheumatologic diseases, C-reactive protein, rheumatoid factor, antinuclear antibody, compleman, uric acid and thyroid hormone levels were determined, and complete blood count and urine analysis were performed. Serum IL-13 levels were measured by ELISA method. The mean age of the patients was 31.65±5.05 years, and the mean age of the control group was 29.38±4.11 years. The mean duration of the disease was 6.03±2.11 years. The mean number of tender fibromyalgia trigger points was 13.72±1.8. The mean serum IL-13 levels in the patient and control groups were 180.69±57 pg/ml and 254.13±82.25 pg/ml, respectively (p=0.001). In our particular experience serum IL-13 levels are low in patients with fibromyalgia, and this condition may be related to chronic subclinical inflammation.
Bookmark/Search this post with
Abstract (Original Language): 
Fibromiyalji yaygın kronik ağrı ve muayenede spesifik hassas noktalar ile karakterli bir hastalıktır. Fibromiyaljinin patogenezi bilinmemekte, ancak genetik yatkınlığın, travmanın, psikopatolojik nedenlerin, viral enfeksiyonların ve immünolojik mekanizmaların patogenezde rolü olabileceği düşünülmektedir. Bu çalışmanın amacı fibromiyaljili hastalarda serum interlökin-13 (IL- 13) düzeylerini tespit etmekti. Fibromiyalji tanısı almış 29 bayan hasta ve 26 sağlıklı bayan çalışmaya alındı. Olası otoimmün ve romatolojik hastalıkların dışlanması için C-reaktif protein, romatoid faktör, antinükleer antikor, kompleman, ürik asid ve tiroid hormon düzeyleri belirlendi, tam kan sayımı ve idrar tetkikleri yapıldı. Serum IL-13 düzeyleri ELISA yöntemi ile ölçüldü. Hastaların yaş ortalaması 31.65±5.05 yıl, kontrol grubunun yaş ortalaması ise 29.38±4.11 yıl idi. Ortalama hastalık süresi 6.03±2.11 yıldı. Hastaların hassas fibromiyalji tetik nokta sayıları ortalama 13.72±1.81 olarak bulundu. Hasta ve kontrol gruplarında ortalama serum IL-13 düzeyleri sırası ile 180.69±57 pg/ml ve 254.13±82.25 pg/ml olarak saptandı (p=0.001). Bu sonuçlara göre fibromiyaljili hastalarda serum IL-13 düzeyleri düşüktür ve bu durum kronik subklinik inflamasyonla ilişkili olabilir.
FULL TEXT (PDF): 
PDF icon arastirmax-fibromiyaljili-hastalarda-serum-interlokin-13-il-13-duzeyleri.pdf
  • 4
257-260
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman
S, Silver D, Weisman MH. Cytokines play an
aetiopathogenetic role in fibromyalgia: a hypothesis
and pilot study. Rheumatology 2001; 40: 743-749.
2. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM,
Shah S. Genetic linkage analysis of multicase families
with fibromyalgia syndrome. J Rheumatol 1999; 26:
408-412.
3. Culclasure TF, Enzenauer RJ, West SG. Post-traumatic
stress disorder presenting as fibromyalgia syndrome.
Am J Med 1993; 94: 548-549.
4. Weinberger LM. Traumatic fibromyositis: a critical
review of an enigmatic concept. West J Med 1997; 127:
99-103.260 • Aralık 2008 • Gülhane Tıp Derg Keskin ve ark.
5. Gur A, Karakoç M, Nas K, et al. Cytokines and depression
in cases with fibromyalgia. J Rheumatol 2002; 29:
358-361.
6. Goldenberg DL. Fibromyalgia and its relation to
chronic fatigue syndrome, viral illness and immune
abnormalities. J Rheumatol Suppl 1989; 19: 91-93.
7. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ.
Regional blood flow and cytokines in young females
with fibromyalgia. Clin Exp Rheumatol 2002; 20:
753-760.
8. Salemi S, Rethage J, Wollina U, et al. Detection of
interleukin 1ß (IL-1ß), IL-6, and tumor necrosis factor-
α in skin of patients with fibromyalgia. J Rheumatol
2003; 30: 146-150.
9. Su SY, Chen JJ, Lai CC, Chen CM, Tsai FJ. The
association between fibromyalgia and polymorphism
of monoamine oxidase A and interleukin-4. Clin
Rheumatol 2007; 26: 12-16.
10. Uçeyler N, Valenza R, Stock M, Schedel R, Sprotte
G, Sommer C. Reduced levels of antiinflammatory
cytokines in patients with chronic widespread pain.
Arthritis Rheum 2006; 54: 2656-2664.
11. Caro XJ. Is there an immunologic component to the
fibrositis syndrome? Rheum Dis Clin North Am 1989;
15: 169-186.
12. Clauw DJ, Chrousos GP. Chronic pain and fatigue
syndromes: overlapping clinical and neuroendocrine
features and potential pathogenic mechanisms.
Neuroimmunomodulation 1997; 4: 134-153.
13. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y,
Buskila D. Autonomic dysfunction in patients with
fibromyalgia: application of power spectral analysis of
heart rate variability. Semin Arthritis Rheum 2000; 29:
217-227.
14. Rowe PC, Bou Holaigah I, Kan JS, Calkins H. Is neurally
mediated hypotension an unrecognized cause of
chronic fatigue? Lancet 1995; 345: 623-624.
15. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL,
Chrousos GP, Pillemer SR. Responses of the sympathetic
nervous system and the hypothalamic-pituitary-adrenal
axis to interleukin-6: a pilot study in fibromyalgia.
Arthritis Rheum 2000; 43: 872-880.
16. Scott LV, Teh J, Reznek R, Martin A, Sohaib A,
Dinan TG. Small adrenal glands in chronic fatigue
syndrome: a preliminary computer tomography study.
Psychoneuroendocrinology 1999; 24: 759-768.
17. Demitrack MA, Dale JK, Straus SE, et al. Evidence for
impaired activation of the hypothalamic-pituitaryadrenal axis in patients with chronic fatigue syndrome.
J Clin Endocrinol Metab 1991; 73: 1224-1234.
18. Buskila D. Fibromyalgia, chronic fatigue syndrome, and
myofascial pain syndrome. Curr Opin Rheumatol 2001;
13: 117-127.
19. Hader N, Rimon D, Kinarty A, Lahat N. Altered
interleukin-2 secretion in patients with fibromyalgia
syndrome. Arthritis Rheum 1991; 34: 866-872.
20. Wallace DJ, Bowman RL, Wormsley SB, Peter JB.
Cytokines and immune regulation in patients with
fibrositis. Arthritis Rheum 1989; 32: 1334-1335.
21. Coetzer P, Lockyer I, Schorn D, Boshoff L. Quantitative
disability evaluation of syndromes presenting with
chronic fatigue. S Afr Med J 2000; 90: 1034-1052.
22. Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini
G. Interleukin-13 in autoimmune rheumatic diseases:
relationship with autoantibody profile. Clin Exp
Rheumatol 2002; 20: 213-216.
23. Punnonen J, Aversa G, Cocks BG, et al. Interleukin-
13 induces interleukin-4-independent IgG4 and Ig
E synthesis and CD23 expression by human B cells,
but not on T cells. Proc Natl Acad Sci USA 1993; 90:
3730-3734.
24. Zurawski G, de Vries JE. Interleukin-13, an İnterleukin-
4-like cytokine that acts on monocyte and B-cells, but
not on T-cells. Immunol Today 1994; 15: 19-26.
25. McKenzie AN, Culpepper JA, de Waal Malefyt R, et al.
Interleukin-13, a T-cell derived cytokine that regulates
human monocyte and B-cell function. Proc Natl Acad
Sci USA 1993; 90: 3735-3739.
26. Wolfe F, Smythe HA, Yunus MB, et al. The American
College of Rheumatology 1990 criteria for the
classification of fibromyalgia: report of the multicenter
criteria committee. Arthritis Rheum 1990; 33: 160-172.
27. Kishimoto T, Akira S, Narazaki M, et al. Interleukin-
6 family of cytokines and gp 130. Blood 1990; 86:
1243-1254.
28. Cannon JG, Angel JB, Ball RW, Abad LW, Fagioli L,
Komaroff AL. Acute phase responses and cytokine
secretion in chronic fatigue syndrome. J Clin Immunol
1999; 19: 414-421.
29. Cho CC, Janoff EN, Hu SX, et al. Altered cytokine
release in peripheral blood mononuclear cell cultures
from patients with the chronic fatigue. Cytokine 1991;
3: 292-298.
30. Amel Kashipaz MR, Swinden D, Todd I, Powell RJ.
Normal production of inflammatory cytokines in
chronic fatigue and fibromyalgia syndromes determined
by intracellular cytokine staining in short-term cultured
blood mononuclear cells. Clin Exp Immunol 2003; 132:
360-365.
31. Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield
D. Cytokine production and fatigue in patients with
chronic fatigue syndrome and healthy control subjects
in response to exercise. Clin Infect Dis 1994; 18 (Suppl
1): 142-146.
32. Swanink CM, Vercoulen JH, Galama JM, et al.
Lymphocyte subsets, apoptosis, and cytokines in
patients with chronic fatigue syndrome. J Infect Dis
1996; 173: 460-463.
33. Woods JM, Haines GK, Shah MR, et al. Low–level
production of IL 13 in synovial fluid and tissue from
patients with arthritis. Clin Immunopathol 1997; 85:
210-220.
34. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine
patterns in fibromyalgia and their correlation with
clinical manifestations. Clin Exp Rheumatol 2007; 25:
225-230.
35. Dantzer R. Cytokine-induced sickness behavior.
A neuroimmune response to activation of innate
immunity. Eur J Pharmacol 2004; 500: 399-411.
36. Kent S, Bluthé RM, Kelley KW, Dantzer R. Sickness
behavior as a new target for drug development. Trends
Pharmacol Sci 1992; 3: 24-28.

Thank you for copying data from http://www.arastirmax.com